


# Supplementary information, Figure S3



**Fig. S3. *Cds2* EC-specific KO blocks tumor growth and angiogenesis. (a-e)** EC-specific ablation of *Cds2* (**a**) resulted in limited B16 tumor growth (**a**), decreased vessel area (**b** and **e**), reduced tumor size (**c**) and weight (**d**). Quantification of vessel density is shown in (**e**). Schematic diagram (**a**) shows the strategy for genetic ablation of *Cds2* before tumor implantation. TAM, tamoxifen.  $n = 6-8$  tumors from 6-8 mice per group. **(f-j)** Genetic depletion of *Cds2* in ECs (**a**) caused limited TC-1 tumor growth (**f**), decreased vessel area (**g** and **j**) and reduced tumor size (**h**) and weight (**i**). Vessel density was quantified in (**j**).  $n = 5-8$  tumors from 5-8 mice per group. Scale bars, 200  $\mu\text{m}$ . Error bars, mean  $\pm$  SEM.  $*P < 0.05$ ;  $**P < 0.01$ ;  $***P < 0.001$ ;  $****P < 0.0001$ ; ns, not significant ( $P \geq 0.05$ ).